[Prevention of hepatitis B--analysis of cost-effectiveness after liver transplantation].
HBV recurrence, despite immunoprophylaxis which occurred in 67% of our patients, remains the main problem following liver transplantation for HBV infection. Pretransplant viral replication (HBV-DNA) and probably viral mutation may account to some degree for the failures involved in hyperimmunoglobulin prophylaxis. In order to improve the cost/benefit relationship, only HBV-DNA and HBeAG-negative patients should be selected or preoperatively seroconverted by nucleosides (famciclovir, lamivudine); post-operatively a variable HIG prophylaxis should be administered.
Golling
M
M
Chirurgische und Medizinische Universitätsklinik Heidelberg.
Arnold
J C
JC
Rudek
B
B
Theilmann
L
L
Herfarth
C
C
Otto
G
G
D015075:2-Aminopurine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000191:economics; D003362:Cost-Benefit Analysis; D000077595:Famciclovir; D005260:Female; D006509:Hepatitis B / Q000191:economics / Q000517:prevention & control*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage* / Q000191:economics; D016031:Liver Transplantation / Q000191:economics*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000191:economics / Q000517:prevention & control*; D012008:Recurrence
D000998:Antiviral Agents; D019259:Lamivudine; D015075:2-Aminopurine; D000077595:Famciclovir
HBV-Prophylaxe--Kosten/Nutzenanalyse nach Lebertransplantation.